Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Baseline characteristics of the patients^a. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Flow of patients in Halos trial. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Cough-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Dyspnea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Sample photoquadrats. by Oscar Beijbom (767233)

The H₂O₂ content (a) and MDA content (b) in <i>R</i>. <i>pseudoacacia</i> leaves were affected by Pb stress levels and AMF inoculation. by Yurong Yang (300925)

LTP assays with different αSOs. by Femke van Diggelen (6499112)

Annotation accuracy. by Oscar Beijbom (767233)

CHC amounts at the wing cuticle surface depend on Osy function. by Yiwen Wang (666361)

Effect of Acidic Polymers on the Morphology of Laser-Induced Nucleation of Cesium Chloride by Yao Liu (173014)

“…Additionally, we observed that both PESA and PASA were able to decrease crystal growth velocity and the quantity of crystals after laser irradiation. …”

Effect of Acidic Polymers on the Morphology of Laser-Induced Nucleation of Cesium Chloride by Yao Liu (173014)

“…Additionally, we observed that both PESA and PASA were able to decrease crystal growth velocity and the quantity of crystals after laser irradiation. …”

An AFM tip coated with either serum-free CHO cell conditioned media (CHO), serum-free CHO conditioned media containing beta-2 myc-His ectodomain (CHO Beta-2), 100 µg/mL BSA (BSA),... by Keith H. Jansson (571788)

Nullclines in the <i>V</i>₂-<i>h</i> plane for fixed values of <i>V</i>₁ and trajectory of response to pair of EPSGs. by Joshua H. Goldwyn (339094)

“…In these simulations we set . The green trajectory is the response of the model to a pair of EPSGs with time delay of 1.5 ms and amplitude three times that of a unitary auditory nerve fiber input. …”

Junction assembly in 3D cell cultures is severely impaired for W2A mutant. by Stefanie Bunse (491659)

“…Both R14E and V81D/V174D needed twice the Ca²⁺-concentration (0.8 mM) to show a significant increase in roundness emphasizing that in 3D, loss of either X-dimer or the <i>cis</i> interface leads to a decreased Ca²⁺-sensitivity in junction assembly (n for each condition ≥ 4, Mann-Whitney U test, p < 0.05). …”

Propofol PAC in EEG profile of stepwise-increasing propofol dose in human volunteers and accompanying illustrations. by Austin E. Soplata (4676017)

Propofol potentiation of g_GABAA and τ_GABAA enables sustained alpha oscillations on the g_H-background excitation plane. by Austin E. Soplata (4676017)

Effect of U0126 pre-treatment of HTR-8/SVneo cells on invasion in presence or absence of EGF. by Ankita Malik (1863829)

Effect of STAT3 and STAT1 silencing on invasion in presence or absence of EGF. by Ankita Malik (1863829)